Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Fenn, Sebastian ^a   Schiller, Christian B ^c   Griese, Julia J ^c,d   Duerr, Harald ^a   Imhof Jung, Sabine ^a   Gassner, Christian ^a   Moelleken, Joerg ^a   Regula, Joerg Thomas ^a   Schaefer, Wolfgang ^a   Thomas, Markus ^a   Klein, Christian ^b   Hopfner, Karl Peter ^c   Kettenberger, Hubert ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b Roche Glycart   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CROSS REACTING ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THERMOSTABILITY; X RAY DIFFRACTION;

AMINO ACID SEQUENCE; ANGIOPOIETIN-2; ANTIBODIES, BISPECIFIC; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; STATIC ELECTRICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE;

EID: 84876270534     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061953     Document Type: Article

References (35)

1. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W, (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 4.
2. Kontermann R, (2012) Dual targeting strategies with bispecific antibodies. MAbs 4.
3. Padlan EA, (1994) Anatomy of the antibody molecule. Mol Immunol 31: 169-217.
4. Williamson AR, (1976) The biological origin of antibody diversity. Annu Rev Biochem 45: 467-500.
5. Schroeder HW Jr, Cavacini L, (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125: S41-S52.
6. Jefferis R, Lund J, Pound JD, (1998) IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 163: 59-76.
7. van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW, (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557 10.1126/science.1144603.
8. Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U, (2010) Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 38: 84-91 10.1124/dmd.109.029751.
9. Demarest SJ, Glaser SM, (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11: 675-687.
10. Ionescu RM, Vlasak J, Price C, Kirchmeier M, (2008) Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97: 1414-1426.
11. Garber E, Demarest SJ, (2007) A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 355: 751-757.
12. Ewert S, Huber T, Honegger A, Pluckthun A, (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325: 531-553.
13. Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J, (2009) An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell 34: 569-579.
14. Milstein C, Cuello AC, (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540.
15. Suresh MR, Cuello AC, Milstein C, (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 121: 210-228.
16. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C, (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108: 11187-11192.
17. Atwell S, Ridgway JB, Wells JA, Carter P, (1997) Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 270: 26-35 10.1006/jmbi.1997.1116.
18. Carter P, (2001) Bispecific human IgG by design. J Immunol Methods 248: 7-15.
19. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P, (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16: 677-681 10.1038/nbt0798-677.
20. Ridgway JB, Presta LG, Carter P, (1996) 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9: 617-621.
21. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G, (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323: 1610-1614 10.1126/science.1165480.
22. Schneider EL, Lee MS, Baharuddin A, Goetz DH, Farady CJ, Ward M, Wang CI, Craik CS, (2012) A reverse binding motif that contributes to specific protease inhibition by antibodies. J Mol Biol 415: 699-715.
23. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J, (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17: 555-561 10.1038/9858.
24. Stanfield RL, Zemla A, Wilson IA, Rupp B, (2006) Antibody elbow angles are influenced by their light chain class. J Mol Biol 357: 1566-1574.
25. Suhrer SJ, Suhrer SJ, Wiederstein M, Wiederstein M, Gruber M, Gruber M, Sippl MJ, Sippl MJ, (2009) COPS-a novel workbench for explorations in fold space. Nucleic Acids Res 37: W539-W544.
26. Kabsch W, (2010) Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr 66: 133-144.
27. Evans P, (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62: 72-82.
28. Matthews BW, (1968) Solvent content of protein crystals. J Mol Biol 33: 491-497.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ, (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
30. Sali A, Blundell TL, (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
31. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
32. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH, (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
33. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
34. Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P et al. (2011) BUSTER, version Cambridge, U.K.: Global Phasing Ltd.
35. Brunger AT, Adams PD, Adms PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL, (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.